Translational biology of osteosarcoma
Maya Kansara, Michele W Teng, Mark J Smyth, David M Thomas
NATURE REVIEWS CANCER | NATURE PUBLISHING GROUP | Published : 2014
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
Awarded by NHMRC
The authors apologize to those whose work on the biology and clinical aspects of osteosarcoma have advanced the field but could not be cited owing to space limitations. The work of the authors is funded by the National Health and Medical Research Council (NHMRC), Australia. D.M.T. is supported by an NHMRC Senior Research Fellowship (1003929).